Skip to main content
An official website of the United States government
Email

Acquired Resistance to Therapy Network (ARTNet)

Representative image for ARTNet, which focuses on the mechanistic bases of acquired resistance to cancer therapies and disease recurrence.

ARTNet (funded through RFA-CA-21-052/RFA-CA-21-053 by DCB and the NCI Division of Cancer Treatment and Diagnosis) focuses on the mechanistic bases of acquired resistance to cancer therapies and disease recurrence.

Its central goal is to balance basic, pre-clinical, and translational research using an iterative team science structure that will enable hypothesis testing on the biological basis of resistance in clinically relevant model systems.

ARTNet also aims to provide evidence along the shared tumor-tumor microenvironment (TME) continuum to inform new strategies that can be better translated into future clinical trials.

Collectively, the network represents a range of treatment modalities (e.g., chemotherapy, radiation, targeted agents, immunotherapies, combined modalities) and cancer types in pursuit of addressing compelling questions and significant barriers in acquired therapy resistance research.

ARTNet News

ARTNet Podcast Episode 1 - Why Cancer Fights Back: A Conversation with Jeffrey Tyner

In the premiere episode of the ARTNet Podcast, we speak with Dr. Jeffrey Tyner shares insights into how cancer cells adapt and survive treatment, the critical role of the tumor microenvironment in drug resistance, and why understanding resistance mechanisms is essential for developing more durable therapies. The conversation also explores how collaboration across ARTNet is helping researchers connect data, models, and expertise to better understand cancer relapse and treatment failure.

 

ARTNet Digital Media

Learn more about ARTNet via the following digital media platforms:

DCB Contact for ARTNet

For additional information about ARTNet, please contact Dr. Jeff Hildesheim. 

Funded Projects

ARTNet Research Centers (U54s)

InstitutionPrincipal Investigator(s)Center Title
MD Anderson Cancer CenterBoyi Gan, Albert KoongAcquired Resistance to Therapy and Iron (ARTI) Center
MD Anderson Cancer Center Jefferey N. Myers, Vlad C. SandulacheThe Houston Center for Acquired Resistance Research (H-CARR)
Oregon Health and Science University Jeffery W. Tyner, Brian J. Druker, Shannon K. McWeeneyArchitecture and Trajectory of Acquired Resistance to Therapy in AML 
University of California, San Francisco Trever G. Bivona, Jack RothBay Area & Anderson Team Against Acquired Resistance - U54 Program (BAATAAR-UP)
University of Oklahoma Health Sciences Center Pankaj K. SinghPancreatic Cancer ARTNet Center

ARTNet Coordinating and Data Management Center (U24)

InstitutionPrincipal Investigator(s)Center Title
Roswell Park Cancer InstituteAlan D. Hutson, David W. Goodrich, Song Liu, Martin T. MorganCoordinating and Data Management Center for Acquired Resistance to Therapy Network 
  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Acquired Resistance to Therapy Network (ARTNet) was originally published by the National Cancer Institute.”

Email